Boundless Bio Inc (BOLD) - Forward P/S Multiple
Unique patent protection in ecDNA oncogene therapy serves as the primary growth catalyst, although pre-commercialization risks persist. Boundless Bio, Inc. (BOLD) occupies an exclusive niche in tumor combat, leveraging innovative US laboratories and substantial capital. The shift in forward P/S clearly captures the balance of market expectations, while the level acts as a critical benchmark for analyzing the validity of current multiples.
Comprehensive metric breakdowns and analytics for Boundless Bio Inc (BOLD)
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Boundless Bio, Inc.|BOLD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Boundless Bio, Inc.|BOLD - Company Total Debt Obligations|Debt to Book Capitalization Ratio Boundless Bio Inc|BOLD - Company Long-Term Indebtedness|Company Short-Term Debts Boundless Bio|Quick Liquidity Indicator boundlessbio.com
- financial results and valuation multiples details:
BOLD - Net Financial Result|Projected Future Earnings Boundless Bio, Inc.|BOLD - Price to Earnings Ratio|Future Price to Earnings Boundless Bio, Inc|BOLD - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boundless Bio Inc|BOLD - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Boundless Bio|BOLD - Earnings per share for the last 12 months|Quarterly EPS earnings growth boundlessbio.com|BOLD - Earnings per share growth this year|Net earnings per share growth forecast for next year Boundless Bio, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:BOLD (Boundless Bio)
Boundless Bio, Inc. (BOLD) is developing an innovative targeted therapy platform for extrachromosomal DNA to treat resistant forms of cancer, positioning the company as a high-tech asset with long-term potential. The expected P/S metric compares current market capitalization with projected revenue, allowing investors to filter out market noise and determine the extent to which the business is overvalued or undervalued relative to its future cash flows.
Competitor analysis for Boundless Bio, Inc.
Tempus AI, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales QGEN|Ionis Pharma - Forward P/S Multiple|RGEN: Price-to-Projected Revenue Ratio|RNA: Forward P/S Multiple|CRSP - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio GeneDx|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|SRPT (Sarepta Corp) - Forward Price to Sales|Forward P/S Multiple TWST (Twist Bioscience)|Market Cap to Expected Sales Ratio 10xgenomics.com (TXG)|NTLA - Price-to-Projected Revenue Ratio|STOK (Stoke Therapeutics Inc) - Market Cap to Projected Revenue|BLFS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Wave Pharma|Forward Price-to-Revenue Multiple MAZE|sionnatx.com (SION) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PRME|Price-to-Projected Revenue Ratio TSHA (Taysha Gene Therapies Inc)|Price-to-Projected Revenue Ratio uniQure Corp QURE|MeiraGTx Corp (MGTX) - Market Cap to Future Revenue Ratio|RGNX - Price-to-Projected Revenue Ratio|SLDB: Price-to-Projected Revenue Ratio|OCGN: Forward P/S Multiple|Market Cap to Projected Revenue PACB|BNTC (Benitec) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Corp)|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple LXEO (Lexeo Therapeutics, Inc.)|Forward P/S Multiple Korro Bio Inc. KRRO|Editas - Forward P/S Multiple|SLN: Price-to-Projected Revenue Ratio|proqr.com (PRQR) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Codexis (CDXS)|Forward Price-to-Revenue Multiple SGMO|Forward P/S Multiple Nautilus Biotechnology Inc|Price-to-Projected Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Market Cap to Projected Revenue|Forward P/S Multiple GBIO (Generation Bio)|XCUR: Market Cap to Projected Revenue|IMNN - Price-to-Projected Revenue Ratio|PHIO: Price-to-Projected Revenue Ratio|MBIO: Forward P/S Multiple|Market Cap to Future Revenue Ratio TransCode Therapeutics, Inc. (RNAZ)|Price-to-Projected Revenue Ratio Bionano Genomics Inc.|adnas.com (APDN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio bluebird bio (BLUE)|Market Cap to Expected Sales Ratio immunoprecise.com|Omega - Forward Price-to-Revenue Multiple|Forward Price to Sales OMIC|Regulus Therapeutics - Forward P/S Multiple|SYRS: Price-to-Projected Revenue Ratio|TBIO: Forward P/S Multiple|TCON - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Unity Bio
